Vamil Divan
Stock Analyst at Guggenheim
(4.83)
# 79
Out of 5,090 analysts
243
Total ratings
67.05%
Success rate
22.67%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Buy | $206 → $227 | $201.93 | +12.42% | 18 | Dec 5, 2025 | |
| PFE Pfizer | Maintains: Buy | $33 → $35 | $26.03 | +34.46% | 23 | Nov 24, 2025 | |
| JBIO Jade Biosciences | Maintains: Buy | $14 → $17 | $13.50 | +25.93% | 2 | Nov 18, 2025 | |
| ELDN Eledon Pharmaceuticals | Maintains: Buy | $9 → $8 | $1.58 | +406.33% | 1 | Nov 18, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $114 → $115 | $81.77 | +40.64% | 13 | Nov 10, 2025 | |
| SCYX SCYNEXIS | Maintains: Buy | $4 → $3 | $0.66 | +357.60% | 3 | Oct 28, 2025 | |
| ABBV AbbVie | Maintains: Buy | $227 → $242 | $226.08 | +7.04% | 28 | Oct 20, 2025 | |
| SVRA Savara | Maintains: Buy | $8 → $11 | $6.50 | +69.23% | 2 | Sep 9, 2025 | |
| VALN Valneva SE | Maintains: Buy | $14 → $13 | $9.00 | +44.44% | 2 | Sep 8, 2025 | |
| INSM Insmed | Maintains: Buy | $125 → $172 | $204.00 | -15.69% | 7 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $39 | $35.01 | +11.40% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $2.34 | +199.15% | 2 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $288 | $329.89 | -12.70% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $6.23 | +863.08% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $99.72 | +15.32% | 14 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $35.00 | +34.29% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.58 | +179.33% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $44.90 | +35.86% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $21.69 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $4.24 | +513.21% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.33 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $27.44 | -30.76% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $155.51 | -36.98% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $29.52 | +15.18% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.55 | +292.16% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $149.22 | -67.16% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $1,010.31 | -64.76% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $6.51 | -7.83% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $9.55 | +1,512.57% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $6.85 | +118.98% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $31.59 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $28.46 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $8.81 | +70.26% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $52.15 | +16.97% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $3.73 | +2,661.39% | 3 | Jan 17, 2018 |
Johnson & Johnson
Dec 5, 2025
Maintains: Buy
Price Target: $206 → $227
Current: $201.93
Upside: +12.42%
Pfizer
Nov 24, 2025
Maintains: Buy
Price Target: $33 → $35
Current: $26.03
Upside: +34.46%
Jade Biosciences
Nov 18, 2025
Maintains: Buy
Price Target: $14 → $17
Current: $13.50
Upside: +25.93%
Eledon Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $1.58
Upside: +406.33%
ANI Pharmaceuticals
Nov 10, 2025
Maintains: Buy
Price Target: $114 → $115
Current: $81.77
Upside: +40.64%
SCYNEXIS
Oct 28, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.66
Upside: +357.60%
AbbVie
Oct 20, 2025
Maintains: Buy
Price Target: $227 → $242
Current: $226.08
Upside: +7.04%
Savara
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $6.50
Upside: +69.23%
Valneva SE
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $9.00
Upside: +44.44%
Insmed
Sep 8, 2025
Maintains: Buy
Price Target: $125 → $172
Current: $204.00
Upside: -15.69%
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $39
Current: $35.01
Upside: +11.40%
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.34
Upside: +199.15%
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $329.89
Upside: -12.70%
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $6.23
Upside: +863.08%
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $99.72
Upside: +15.32%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $35.00
Upside: +34.29%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $3.58
Upside: +179.33%
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $44.90
Upside: +35.86%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $21.69
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $4.24
Upside: +513.21%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $3.33
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $27.44
Upside: -30.76%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $155.51
Upside: -36.98%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $29.52
Upside: +15.18%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.55
Upside: +292.16%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $149.22
Upside: -67.16%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $1,010.31
Upside: -64.76%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $6.51
Upside: -7.83%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $9.55
Upside: +1,512.57%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $6.85
Upside: +118.98%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $31.59
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $28.46
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $8.81
Upside: +70.26%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $52.15
Upside: +16.97%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $3.73
Upside: +2,661.39%